Sanders John W, Frenck Robert W, Putnam Shannon D, Riddle Mark S, Johnston James R, Ulukan Sefa, Rockabrand David M, Monteville Marshall R, Tribble David R
Department of Infectious Diseases, National Naval Medical Center, 8901 Wisconsin Ave., Bethesda, Maryland 20889, USA.
Clin Infect Dis. 2007 Aug;45(3):294-301. doi: 10.1086/519264.
The recommended treatment for traveler's diarrhea is the combination of an appropriate antibiotic (usually a fluoroquinolone) and loperamide. Azithromycin compared favorably with fluoroquinolones in trials that did not include the use of loperamide, but combination therapy has not, to our knowledge, been studied to date.
A randomized, double-blind trial was conducted at Incirlik Air Base, Turkey, fromJ une 2003 through August 2004. Adults from the United States with noninflammatory diarrhea were randomized to receive a single dose of azithromycin (1000 mg; 106 persons) or levofloxacin (500 mg; 101 persons) plus loperamide (4 mg initially and as needed thereafter). Volunteers maintained a symptom diary and were evaluated on days 1, 3, and 7 after treatment.
No differences were noted with respect to pretreatment symptoms or pathogen distribution. Enterotoxigenic Escherichia coli was the most common pathogen isolated (from 45% of patients in the azithromycin group and 42% of patients in the levofloxacin group), and Campylobacter species was the second most common pathogen isolated (from 6% of patients in the azithromycin group and 9% of patients in the levofloxacin group). Median time to last diarrheal stool (azithromycin group, 13 h; levofloxacin group, 3 h), median time to resolution of associated symptoms (2 days), and additional loperamide usage (azithromycin group, 39% of patients; levofloxacin group, 34% of patients) were similar between groups. Azithromycin use was associated with more nausea in the 30 min after dosing (azithromycin group, 8% of patients; levofloxacin group, 1% of patients; Pp.004), but no vomiting or other adverse events were noted in either group.
Single-dose treatment with azithromycin (1000 mg) and loperamide is as effective as single-dose treatment with levofloxacin (500 mg) and loperamide for noninflammatory diarrhea. Although nausea after dosing is uncommon, it is more frequently associated with azithromycin than with levofloxacin. Future studies should focus on determining whether lower doses of azithromycin would decrease the frequency of nausea and decrease treatment costs without affecting efficacy.
旅行者腹泻的推荐治疗方法是使用适当的抗生素(通常是氟喹诺酮类)与洛哌丁胺联合使用。在未使用洛哌丁胺的试验中,阿奇霉素与氟喹诺酮类药物相比效果良好,但据我们所知,联合治疗迄今尚未得到研究。
2003年6月至2004年8月在土耳其因吉尔利克空军基地进行了一项随机双盲试验。来自美国的患有非炎性腹泻的成年人被随机分配接受单剂量阿奇霉素(1000毫克;106人)或左氧氟沙星(500毫克;101人)加洛哌丁胺(初始剂量4毫克,此后按需服用)。志愿者记录症状日记,并在治疗后第1、3和7天接受评估。
在预处理症状或病原体分布方面未发现差异。产肠毒素大肠杆菌是分离出的最常见病原体(阿奇霉素组45%的患者,左氧氟沙星组42%的患者),弯曲杆菌属是第二常见病原体(阿奇霉素组6%的患者,左氧氟沙星组9%的患者)。两组之间最后一次腹泻大便的中位时间(阿奇霉素组13小时;左氧氟沙星组3小时)、相关症状缓解的中位时间(2天)以及额外使用洛哌丁胺的情况(阿奇霉素组39%的患者;左氧氟沙星组34%的患者)相似。服用阿奇霉素后30分钟内恶心的情况更多(阿奇霉素组8%的患者;左氧氟沙星组1%的患者;P = 0.004),但两组均未出现呕吐或其他不良事件。
单剂量阿奇霉素(1000毫克)和洛哌丁胺治疗非炎性腹泻的效果与单剂量左氧氟沙星(500毫克)和洛哌丁胺相同。虽然服药后恶心并不常见,但与阿奇霉素的关联比与左氧氟沙星更频繁。未来的研究应集中于确定较低剂量的阿奇霉素是否会降低恶心的频率并降低治疗成本而不影响疗效。